PLSE · XBRL financial data

Pulse Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PLSE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	0	0*	0	0	0	0*	0	0	86	year only	401	434
Cost of revenue	0	0*	—	—	0	0*	0	0	279	260*	370	273
Research and development	7,472	7,799*	6,741	7,230	7,703	10,662*	10,313	12,088	11,393	10,927*	12,590	16,976
Selling, general and administrative	—	—	—	—	5,952	9,599*	7,731	8,187	8,781	7,330*	6,591	8,457
General and administrative	3,780	4,734*	3,874	4,496	5,952	9,599*	7,731	8,187	—	—	—	—
Operating income (loss)	(11,252)	(12,533)*	(10,615)	(11,726)	(13,655)	(20,261)*	(18,044)	(20,275)	(20,367)	(18,253)*	(19,150)	(25,272)
Other income (expense)	—	—	—	—	(1)	(10)*	(6)	(22)	(19)	(5)*	(24)	15
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	—	year only	—	—
Net income (loss)	(10,566)	(11,933)*	(10,137)	(11,383)	(12,680)	(19,385)*	(16,795)	(19,168)	(19,385)	(17,433)*	(18,581)	(24,657)
Earnings per share, basic USD per share	(0.19)	(0.22)*	(0.18)	(0.20)	(0.21)	(0.32)*	(0.25)	(0.28)	(0.29)	(0.26)*	(0.27)	(0.36)
Weighted average shares, basic thousands of shares	54,923	55,057*	55,172	57,180	61,066	60,126*	67,126	67,276	67,385	67,787*	67,995	69,200

Balance sheet

CSV

Fiscal quarters (PLSE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	50,386	44,365	34,885	26,196	79,033	118,038	119,279	106,349	95,214	80,735	68,319	101,620
Accounts receivable	—	—	—	—	—	0	—	—	15	274	157	122
Inventory	—	—	—	—	—	0	30	51	57	136	206	236
Prepaid and other current assets	1,237	963	964	1,043	1,381	1,411	1,600	1,760	1,871	2,276	2,448	3,722
Total current assets	51,623	45,328	35,849	27,239	80,414	119,449	120,909	108,160	97,157	83,421	71,130	105,700
Property and equipment, net	1,648	1,528	1,400	1,313	1,221	1,160	1,062	1,109	1,055	1,051	1,016	1,063
Right-of-use asset	7,466	7,256	7,040	6,818	6,588	7,163	6,889	6,607	6,316	6,010	5,702	5,385
Goodwill	2,791	2,791	2,791	2,791	2,791	2,791	2,791	2,791	2,791	2,791	2,791	2,791
Total assets	65,945	59,154	49,164	40,428	93,046	132,460	133,383	120,251	108,765	94,539	81,622	115,564
Accounts payable	1,412	1,836	1,712	1,637	1,727	1,673	2,370	2,742	2,978	2,777	2,761	2,832
Accrued liabilities	3,004	3,814	2,268	3,179	3,821	7,027	3,984	4,777	5,203	3,576	5,408	6,460
Total current liabilities	5,432	6,708	5,081	5,962	6,741	10,055	7,760	8,978	9,700	7,923	9,796	10,978
Lease liability, non-current	8,368	8,086	7,796	7,497	7,174	7,543	7,171	6,786	6,371	5,960	5,528	5,086
Total liabilities	13,800	14,794	12,877	13,459	13,915	17,598	14,931	15,764	16,071	13,883	15,324	16,064
Accumulated deficit	(324,982)	(336,915)	(347,052)	(358,435)	(371,115)	(390,500)	(407,295)	(426,463)	(445,848)	(463,281)	(481,862)	(506,519)
Total stockholders' equity	52,145	44,360	36,287	26,969	79,131	114,862	118,452	104,487	92,694	80,656	66,298	99,500
Total liabilities and equity	65,945	59,154	49,164	40,428	93,046	132,460	133,383	120,251	108,765	94,539	81,622	115,564
Common shares outstanding (cover page) thousands of shares	54,991	55,225	55,225	61,290	61,517	67,274	67,274	67,278	67,768	67,989	69,210	71,323

Cash flows

CSV

Fiscal quarters (PLSE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(10,566)	(11,933)*	(10,137)	(11,383)	(12,680)	(19,385)*	(16,795)	(19,168)	(19,385)	(17,433)*	(18,581)	(24,657)
Stock-based compensation	1,798*	3,344*	1,759	2,052*	2,982*	6,793*	5,681	5,189*	5,617*	4,970*	1,912	4,973*
Net cash from operating activities	(10,487)*	(6,782)*	(9,780)	(8,395)*	(9,024)*	(9,144)*	(13,521)	(12,807)*	(13,039)*	(14,755)*	(14,595)	(18,709)*
Purchases of property and equipment	23*	43*	5	29*	38*	53*	45	103*	62*	105*	33	90*
Net cash from investing activities	(23)*	(43)*	(5)	(29)*	(38)*	(53)*	(45)	(123)*	(62)*	(105)*	(33)	(90)*
Proceeds from issuing common stock	0*	0*	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	2,149*	804*	305	(265)*	61,899*	48,202*	14,807	0*	1,966*	381*	2,212	52,100*
Net change in cash	(8,361)*	(6,021)*	(9,480)	(8,689)*	52,837*	39,005*	1,241	(12,930)*	(11,135)*	(14,479)*	(12,416)	33,301*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Pulse Biosciences	101,620	434	(18,709)*	71.3M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
NutriBand	3,422	438	(585)*	12.2M	—	Q2 FY27 10-QJul 31, 2026
Butterfly Network	122,301	32,598	(2,266)*	not reported	10.3 quarters	Q3 FY26 10-QSep 30, 2026
Ceribell	41,989	29,341	(13,078)*	38.8M	7.8 quarters	Q3 FY26 10-QSep 30, 2026
Delcath Systems	47,521	29,133	5,712*	34.7M	—	Q2 FY26 10-QJun 30, 2026
Orthopediatrics	17,141	72,661	4,506*	26.1M	—	Q3 FY26 10-QSep 30, 2026
Axogen	328,888	75,834	16,536*	59.7M	—	Q3 FY26 10-QSep 30, 2026
Angiodynamics	33,973	80,915	(15,330)	42.1M	2.2 quarters	Q1 FY27 10-QAug 31, 2026
Orthofix Medical	103,810	210,933	(6,224)*	40.7M	16.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.